CompletedPhase 2

Persistent Pleural Effusion Treatment Following Cardiothoracic Surgery by Platelet-Fibrin Glue

Iran19 participantsStarted 2017-05-01

Plain-language summary

Persistent pleural effusion is a life-threatening complication after cardiac surgery. The traditional treatment is chest tube drainage, which may not respond to treatment. This study introduces a new noninvasive approach for treating persistent pleural effusion using platelet-rich plasma fibrin glue (PRP-FG). This method has been successfully applied for the treatment of postoperative persistent chylothorax and pneumothorax in previous studies, which significantly decreased morbidity, mortality, and hospital stay.

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical diagnosis of pleural effusion after cardiac surgery in open-heart surgery * patients who sign an informed consent form Exclusion Criteria: * Hemodynamically unstable patients * Patients who did not sign an informed consent form

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The rate of air leak that is assessed by Cerfolio classification of the air leak by a single observer

Timeframe: within 48 hours after application of platelet-rich plasma

Rate of radiolucency

Timeframe: within 48 hours after application of platelet-rich plasma

Patient hospitalization time

Timeframe: From the time the patient is admitted to the hospital to the time of discharge

Percentage of patients completely recovered

Timeframe: Through study completion, an average of 40 weeks

Percentage of untreated patients who died

Timeframe: Through study completion, an average of 40 weeks

The number of injections until the bubble stops

Timeframe: Through study completion, an average of 40 weeks

Trial details

NCT IDNCT06449131

SponsorDaryoush Hamidi Alamdari, PhD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-05-01

View on ClinicalTrials.gov More Pleural Effusion trials

Plain-language summary

Who can participate

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

The rate of air leak that is assessed by Cerfolio classification of the air leak by a single observer

Timeframe: within 48 hours after application of platelet-rich plasma

Rate of radiolucency

Timeframe: within 48 hours after application of platelet-rich plasma

Patient hospitalization time

Timeframe: From the time the patient is admitted to the hospital to the time of discharge

Percentage of patients completely recovered

Timeframe: Through study completion, an average of 40 weeks

Percentage of untreated patients who died

Timeframe: Through study completion, an average of 40 weeks

The number of injections until the bubble stops

Timeframe: Through study completion, an average of 40 weeks